Secukinumab belongs to a class of medicines called biologics. Biologics are genetically-engineered proteins. Secukinumab works by blocking the activity of a protein called interleukin (IL) 17A.IL-17A levels are increased in diseases such as psoriasis, psoriatic arthritis and ankylosing spondylitis. Secukinumab blocks IL-17A and helps to reduce the activity of the immune system and the symptoms of the diseases.
It may be used alone or together with other DMARDs.
Subscribe to our mailing list to get the updates to your email inbox...
SHP-Head Office, 167 Jalan Bukit Merah Connection One (Tower 5), #15-10, Singapore 150167